Latest news with #Belbuca
Time Business News
11-06-2025
- Health
- Time Business News
How to Stage an Intervention: Tips for Families
Understanding the Purpose of an Intervention An intervention is not an ambush. It's a lifeline. Families often turn to interventions when a loved one is spiraling into substance use, compulsive behavior, or mental health decline. The emotional terrain is treacherous, littered with fear, guilt, and denial. The purpose of an intervention is not to shame or coerce, but to offer a path out of chaos and into recovery. The primary objective is clarity: the individual must understand how their actions are impacting themselves and those around them. Treatment is the destination—not blame, punishment, or retaliation. Framing the intervention with compassion and intention is paramount. Choosing the Right Treatment Option for Opioid Dependence When comparing Belbuca and Suboxone, it's essential to understand their distinct roles in treating opioid dependence. Belbuca is a buccal film containing buprenorphine, primarily used for chronic pain management, whereas Suboxone combines buprenorphine and naloxone to reduce misuse potential and is FDA-approved for opioid use disorder. The choice between Belbuca vs Suboxone depends on individual needs, with Suboxone being more commonly prescribed for addiction treatment. Belbuca may be better suited for patients who require long-term pain relief without the risk of euphoria. Consulting a healthcare provider is crucial for determining the most effective and safe treatment path. Identifying the Right Time for an Intervention There is no perfect moment, but there are red flags that signal urgency. Repeated absences from work, increasing isolation, unexplained financial trouble, legal issues, or erratic behavior may indicate deepening issues. The longer the family waits, the more entrenched the behavior becomes. Timing is critical. Avoid launching an intervention during an argument, after a traumatic event, or when the individual is intoxicated. Intervene during a moment of relative calm, when the person is sober and more likely to process information without emotional overflow. Assembling the Right Intervention Team An effective intervention begins with the right people. Select individuals who hold emotional significance to the person in crisis—siblings, close friends, parents, or partners. Emotional volatility must be screened out; participants must be grounded, calm, and resolute. In many cases, involving a professional interventionist is not only helpful but essential. These experts guide the group, facilitate structure, and provide a neutral voice during potential emotional escalation. Their presence often legitimizes the seriousness of the moment and can prevent derailment. Planning the Intervention Strategically Precision matters. Each participant should prepare a statement that expresses love, concern, and the impact of the individual's behavior—free from accusation or vitriol. These statements should be practiced and revised to balance emotion with clarity. Boundaries must be drawn with unwavering firmness. For example: 'If you choose not to enter treatment, I will no longer provide financial support.' These consequences are not threats—they are self-preservation strategies that reinforce the urgency of the situation. Practice is vital. Rehearse the intervention multiple times to fine-tune tone, timing, and flow. Everyone must remain on message. Consistency disarms denial. Choosing an Appropriate Setting Environment shapes experience. Select a setting that is private, quiet, and emotionally neutral. A family living room may feel too personal or triggering. Consider a therapist's office, a church room, or a private rented space that allows for uninterrupted conversation. Safety is paramount. Have transportation arranged if treatment is accepted. Remove potential triggers, such as substances, weapons, or emotionally charged memorabilia. Confidentiality should be emphasized to avoid shame or social fallout. Conducting the Intervention Begin with love. Every word must be steeped in sincerity. The person may react with anger, tears, denial, or silence. Stay composed. Avoid engaging in arguments or allowing the conversation to spiral into blame. If the individual becomes defensive, re-center the dialogue. Use phrases like, 'We're here because we care,' or 'This is not about judgment—it's about your life.' Have a treatment plan ready. Whether it's detox, inpatient rehab, or therapy, clarity in next steps reduces hesitation. The offer of help must be immediate. Delay can breed indecision. After the Intervention: What Comes Next If the person agrees to treatment, act swiftly. Transportation should be arranged, logistics handled, and emotional support offered. If they refuse, enforce the boundaries discussed. Allowing the status quo to persist invalidates the intervention's impact. Support doesn't end with a 'yes.' Families should seek therapy, join support groups, and educate themselves about recovery. Encouragement should be steadfast but not smothering. Progress is not linear; patience is critical. Finding the Right Support for Opioid Recovery Accessing proper care for opioid addiction is crucial, and many individuals seek compassionate professionals who provide both effective treatment and affordable options. One major concern is finding suboxone doctors that take insurance near me , making treatment financially accessible and consistent. These doctors specialize in medication-assisted treatment, helping patients manage withdrawal symptoms and reduce cravings in a supportive environment. By accepting insurance, these providers remove a significant barrier to recovery, allowing more people to receive the help they need without undue financial stress. With the right medical support, long-term recovery becomes a more achievable goal. Conclusion An intervention is an act of love wrapped in courage. It demands preparation, unity, and emotional discipline. When families stand together with one voice and a clear path forward, they become catalysts for change. Even if the answer is 'no' today, the seed of recovery is planted—and with persistent support, it can one day bloom. TIME BUSINESS NEWS
Yahoo
10-06-2025
- Business
- Yahoo
COLL Q1 Earnings Call: ADHD Portfolio Drives Growth, Management Details Capital Deployment Priorities
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) reported Q1 CY2025 results topping the market's revenue expectations , with sales up 22.7% year on year to $177.8 million. The company expects the full year's revenue to be around $742.5 million, close to analysts' estimates. Its non-GAAP profit of $1.49 per share was 2.8% above analysts' consensus estimates. Is now the time to buy COLL? Find out in our full research report (it's free). Revenue: $177.8 million vs analyst estimates of $172.8 million (22.7% year-on-year growth, 2.9% beat) Adjusted EPS: $1.49 vs analyst estimates of $1.45 (2.8% beat) Adjusted EBITDA: $95.15 million vs analyst estimates of $96.5 million (53.5% margin, 1.4% miss) The company reconfirmed its revenue guidance for the full year of $742.5 million at the midpoint EBITDA guidance for the full year is $442.5 million at the midpoint, above analyst estimates of $438.5 million Operating Margin: 12.2%, down from 34.1% in the same quarter last year Market Capitalization: $978.4 million Collegium Pharmaceutical's first quarter performance was driven by continued momentum in its newly acquired ADHD treatment Jornay PM, alongside stable contributions from its established pain management portfolio. On the call, CEO Vikram Karnani highlighted that Jornay PM delivered 24% year-over-year prescription growth and now accounts for a growing share of the company's overall revenue. Karnani credited targeted sales force expansion and increased prescriber engagement as keys to this performance, stating, 'We recently completed the expansion of our Jornay sales force, adding approximately 55 new sales representatives… now fully trained, deployed and focused on accelerating further prescription growth.' The pain portfolio, including Belbuca, Xtampza ER, and Nucynta, provided steady revenue and cash flow, allowing for continued investment in growth initiatives. Looking ahead, management's guidance is anchored by expectations for continued growth from Jornay PM, with investments in sales and marketing expected to drive prescription gains through 2025 and beyond. Karnani emphasized, 'Our targeted investments throughout 2025, including our expanded sales force and marketing efforts, position Jornay for both near-term growth and significant momentum in 2026 and beyond.' CFO Colleen Tupper noted that operating expenses will remain elevated as the company supports these initiatives but anticipates a downward trend in spending during the second half of the year. The team also pointed to durable cash flows from the pain portfolio, a disciplined approach to business development, and opportunistic share repurchases as key levers supporting future performance and shareholder value. Management attributed the quarter's results to rapid prescription growth for Jornay PM, ongoing durability in pain products, and investments in commercial capabilities. Several leadership and board changes were also highlighted as positioning the company for future growth. Jornay PM prescription surge: The ADHD medicine Jornay PM saw 24% year-over-year prescription growth, with net revenue reaching $28.5 million. Management linked this performance to an expanded and fully trained sales force and increased prescriber engagement. Pain portfolio stability: The legacy pain management products—Belbuca, Xtampza ER, and Nucynta—delivered low-single-digit revenue growth. Despite a declining overall pain market, these products continued to provide a reliable financial foundation, supported by recent extensions of market exclusivity for certain drugs. Sales force investment: The ADHD-focused sales force was expanded by 55 representatives, now totaling 180, allowing Collegium to increase its healthcare provider targets from 17,000 to 21,000. Management expects the full impact of this increase to be realized in late 2025 and into 2026. Leadership and board transitions: The company announced several changes, including the retirement of founder Michael Heffernan as Chairman, nomination of Gino Santini as Chairman, and the addition of new executive leaders to bolster strategic and commercial capabilities. Capital allocation priorities: Management highlighted ongoing investments in Jornay, rapid debt repayment, and the initiation of a $25 million accelerated share repurchase program as core elements of its capital deployment strategy. Collegium's outlook relies on continued expansion of Jornay PM in ADHD, disciplined investment in commercial activities, and maintaining stable returns from its pain portfolio. Jornay growth initiatives: Management expects prescription growth from Jornay PM to accelerate as the expanded sales force reaches more providers and new marketing campaigns target patients and caregivers, particularly around the back-to-school season. The company believes these efforts will lay the groundwork for sustained revenue momentum into 2026. Pain portfolio durability: Despite broader market declines, Collegium anticipates ongoing stable cash flows from its pain products due to product differentiation, market exclusivity, and a strong prescriber base. Management views these products as supporting continued investment and potential business development. Capital deployment flexibility: Management is committed to allocating capital between organic growth, opportunistic acquisitions, and share repurchases. The leadership team indicated willingness to increase leverage for the right acquisition opportunity, supported by strong operating cash flow and a declining net debt ratio. Looking ahead, the StockStory team will be tracking (1) the effectiveness of the expanded Jornay PM sales force and marketing campaigns, especially during the seasonally important back-to-school period; (2) resilience of the pain portfolio as market exclusivities extend and generic pressures mount; and (3) progress on capital deployment, including potential acquisitions and execution of the accelerated share repurchase program. The trajectory of operating expenses as investments scale will also be a key area of focus. Collegium Pharmaceutical currently trades at a forward P/E ratio of 4.2×. Is the company at an inflection point that warrants a buy or sell? Find out in our full research report (it's free). Market indices reached historic highs following Donald Trump's presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth. While this has caused many investors to adopt a "fearful" wait-and-see approach, we're leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.
Time Business News
01-05-2025
- Health
- Time Business News
NJ Faith-Based Recovery Programs: Hope and Healing
Introduction: The Rise of Faith-Based Recovery Programs in New Jersey Addiction is a pervasive issue in New Jersey, affecting individuals from all walks of life. While there are numerous pathways to recovery, faith-based recovery programs have emerged as a powerful source of hope and healing for many. These programs, grounded in spirituality and guided by religious principles, offer a unique approach that blends psychological support with spiritual guidance. The increasing popularity of faith-based recovery programs across the state signifies not only their effectiveness but also their ability to provide a holistic healing experience. When it comes to managing opioid dependence, Belbuca and Suboxone are two options that serve different purposes. Belbuca is a buprenorphine-based medication delivered through a buccal film, designed to treat opioid addiction while reducing the risk of misuse. belbuca vs suboxone, on the other hand, combines buprenorphine with naloxone and is typically administered as a sublingual film or tablet. Both medications help reduce cravings and withdrawal symptoms, but they differ in their formulation and usage. Belbuca is used primarily for opioid dependence, whereas Suboxone, with its added naloxone, is intended to deter misuse, making it a preferred choice in certain situations. Understanding Faith-Based Recovery Programs Faith-based recovery programs differ from traditional, secular addiction treatment methods by incorporating religious teachings and spiritual practices into the recovery process. These programs often align with Christian, Jewish, or other faith traditions, although they may vary in their specific religious approach. The core principles of faith-based recovery include the belief that healing begins with spiritual renewal, the importance of a higher power, and the need for self-reflection and transformation. In contrast to secular programs, which often focus primarily on behavioral and psychological interventions, faith-based recovery integrates spiritual nourishment as a key element of the healing journey. The Role of Spirituality in Addiction Recovery Spirituality plays a vital role in many faith-based recovery programs, providing a sense of purpose, hope, and connection to something greater than oneself. The belief in a higher power fosters resilience, helping individuals navigate the challenges of addiction recovery. For many, spirituality offers the strength to overcome the feelings of hopelessness and isolation that often accompany substance abuse. Faith-based recovery emphasizes the power of prayer, meditation, and reflection, all of which can help individuals cultivate inner peace and clarity as they move forward in their recovery process. These practices can serve as anchors during difficult times, offering comfort and guidance on the path to healing. Notable Faith-Based Recovery Programs in New Jersey New Jersey is home to several faith-based recovery programs that have made significant impacts on the lives of individuals struggling with addiction. Among these, programs like 'New Hope Recovery' and 'The Samaritan Center' stand out for their commitment to providing compassionate care rooted in Christian principles. These programs offer a wide range of services, from detoxification and rehabilitation to long-term recovery support, all infused with a strong spiritual foundation. One of the most well-known success stories from the state is the story of a participant at 'New Hope Recovery,' who overcame a decade-long battle with addiction through the program's blend of counseling, prayer, and community support. The success of such programs speaks to the power of combining faith and treatment in the healing process, allowing individuals to rebuild their lives with the support of both a spiritual community and professional care. Supportive Services and Community Building Faith-based recovery programs are not just about the individual—they also emphasize the importance of community. These programs provide group counseling sessions, mentorship, and peer support groups, creating a safe and supportive environment for individuals to share their struggles and triumphs. The sense of belonging and accountability that comes from being part of a faith-based recovery group is a cornerstone of the healing process. Mentorship programs, often led by those who have already experienced recovery, offer guidance and encouragement, helping participants navigate the challenges of sobriety and personal growth. The support of a faith-based community also extends beyond the recovery process itself. Many programs offer continued spiritual guidance, post-recovery counseling, and access to resources for reintegration into society. This ongoing support network fosters long-term recovery and provides individuals with the tools they need to maintain their sobriety and rebuild their lives. Challenges and Criticisms of Faith-Based Programs Despite the many successes of faith-based recovery programs, they are not without their criticisms. One common concern is that these programs may not be inclusive enough for individuals of different faiths or those who do not adhere to a religious belief system. Some critics argue that a strong religious focus might alienate individuals who do not share the same faith, potentially limiting the program's effectiveness. Additionally, there are concerns about the scientific validity of the methods used in faith-based recovery programs. While many participants report positive outcomes, critics argue that there is insufficient empirical evidence to support the effectiveness of spirituality in addiction recovery when compared to more conventional, evidence-based treatments. Despite these challenges, many faith-based recovery programs in New Jersey have made significant strides in addressing inclusivity and adapting their approaches to meet the needs of a diverse population. Programs are increasingly offering non-denominational options and integrating evidence-based therapeutic practices alongside spiritual teachings, creating a more balanced and inclusive approach to healing. Accessing Affordable Addiction Treatment Finding the right addiction treatment can feel daunting, especially when trying to navigate insurance coverage and medical options. If you're seeking opioid addiction treatment and have United Healthcare insurance, locating a provider who accepts your plan is crucial for managing costs. There are many Suboxone doctors that take United Healthcare near me , making it easier to find support in your area. Suboxone is an effective medication used in opioid recovery, and with the help of a provider who accepts your insurance, you can access the treatment you need without the added financial stress. Conclusion: The Future of Faith-Based Recovery in New Jersey Faith-based recovery programs are poised to play an increasingly important role in New Jersey's addiction recovery landscape. As more individuals seek holistic healing methods, the integration of spirituality and traditional treatment approaches is gaining acceptance and recognition. The future of faith-based recovery in New Jersey looks promising, with many programs expanding their reach and resources to serve a broader population. The continued success of faith-based programs in helping individuals overcome addiction highlights the power of spiritual healing in conjunction with professional support. As these programs evolve and adapt to the needs of a diverse society, they will undoubtedly remain a cornerstone of the state's efforts to address the complex issue of addiction. The hope and healing offered by these programs provide a pathway to recovery that encompasses both the mind and the spirit, offering individuals a chance to rebuild their lives with faith, community, and resilience. TIME BUSINESS NEWS
